Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Topotecan Plus Carboplatin In Comparison To Standard Therapy (Paclitaxel Plus Carboplatin Or Gemcitabine Plus Carboplatin) In The Therapy Of Patients With Platinum Sensitive Recurrent Epithelial Ovarian Cancer, Peritoneal Carcinoma or fallopian tube cancer

Next Previous
Trial Profile

Topotecan Plus Carboplatin In Comparison To Standard Therapy (Paclitaxel Plus Carboplatin Or Gemcitabine Plus Carboplatin) In The Therapy Of Patients With Platinum Sensitive Recurrent Epithelial Ovarian Cancer, Peritoneal Carcinoma or fallopian tube cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Topotecan (Primary) ; Doxorubicin; Gemcitabine; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HECTOR

Most Recent Events

  • 26 Oct 2016 Results assessing tolerabilty of combination of Topotecan and Carboplatin published in the Annals of Oncology (2016).
  • 14 Nov 2013 Planned End Date changed from 1 Sep 2013 to 1 Sep 2015 as reported by ClinicalTrials.gov.
  • 26 Jul 2012 Planned end date changed from 1 Sep 2011 to 1 Sep 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top